Incanthera는 Comm'l Update/Revenue F'cast를 제공합니다.
월 25 2024
이뮤파마 PLC
("임뮤파마" 또는 "회사")
Incanthera Provides Commercial Update
and Revenue Forecasts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc ("Incanthera"), the dermatology and oncology specialist, in which ImmuPharma currently holds a 10.8% shareholding.
Within the announcement, Incanthera announces an update on its commercial skincare deal, announced in December 2023, with Marionnaud (part of the A.S. Watson Group).
Under the terms of the deal, Skin + CELL will be initially launched in c. 100 of Marionnaud's stores in Switzerland and Austria, followed by a planned roll out into the remaining 1,100 European stores, with subsequent anticipated roll outs into major Asian markets.
Incanthera has announced that the first order from Marionnaud has now doubled from 25,000 units to 50,000 units due to the strong demand anticipated by Marionnaud's management and that this first order, on track to be delivered during Q2 2024, will generate c. £2m revenue for Incanthera.
Incanthera also confirms that it projects revenues of £10m and profitability, for the financial year ("FY") to 31 March 2025, growing to revenues of £33m and increased profitability, in the following FY to 31 March 2026.
More insight into Incanthera's technology and deal with Marionnaud is illustrated through the initiation of a Research Note by Stanford Capital Partners, which will shortly be available on the Incanthera plc website www.incanthera.com.
Incanthera trades on Aquis Stock Exchange ("AQSE") under the ticker (AQSE:INC). For full details of the announcement, please visit Incanthera's website: https://incanthera.com/investors/regulatory-news/.
Commenting on Incanthera's announcement, Dr Tim Franklin, COO of ImmuPharma said: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."
자세한 내용은 문의하시기 바랍니다 :
|
편집자 주
ImmuPharma PLC 소개
ImmuPharma PLC(LSE AIM: IMM)는 펩타이드 기반 치료제를 발견하고 개발하는 전문 바이오의약품 회사입니다. 회사의 포트폴리오에는 자가면역 질환 및 항감염제를 위한 새로운 펩타이드 치료제가 포함되어 있습니다. 선두 프로그램인 P140(Lupuzor?)은 루푸스 치료를 위한 최초의 자가포식 면역조절제이며 전임상 분석은 동일한 자가포식 작용 메커니즘을 공유하는 다른 많은 자가면역 질환에 대한 치료 활성을 시사합니다.
ImmuPharma에 대한 추가 정보를 보려면 다음을 방문하십시오. www.immupharma.co.uk에서
ImmuPharma의 LEI(법인식별기호) 코드: 213800VZKGHXC7VUS895.
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
Incanthera originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on Incanthera please visit: www.incanthera.com
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.